Patents Assigned to Sugen, Inc.
  • Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
    Patent number: 6716870
    Abstract: The present invention is directed to prodrugs of certain 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: April 6, 2004
    Assignees: Sugen, Inc., Pharmacia & Upjohn Company
    Inventors: Malcolm Wilson Moon, Walter Morozowich, Ping Gao, Marcel Koenig
  • Diagnosis and treatment of AUR1 and/or AUR2 related disorders
    Patent number: 6716575
    Abstract: The present invention relates to AUR1 and/or AUR2 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for AUR1 and/or AUR2 related diseases or conditions characterized by an abnormal interaction between a AUR1 and/or AUR2 polypeptide and a AUR1 and/or AUR2 binding partner.
    Type: Grant
    Filed: January 22, 1998
    Date of Patent: April 6, 2004
    Assignee: Sugen, Inc.
    Inventors: Gregory Plowman, Kevin Mossie
  • Pyrrole substituted 2-indolinone protein kinase inhibitors
    Publication number: 20040063773
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Application
    Filed: April 14, 2003
    Publication date: April 1, 2004
    Applicant: SUGEN, Inc. & Pharmacia & Upjohn Co.
    Inventors: Peng Cho Tang, Todd A. Miller, Xiaoyuan Li, Li Sun, Chung Chen Wei, Shahrzad Shirazian, Congxin Liang, Thomas Vojkovsky, Asaad S. Nematalla, Michael Hawley
  • 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
    Publication number: 20040053924
    Abstract: This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors.
    Type: Application
    Filed: July 21, 2003
    Publication date: March 18, 2004
    Applicant: SUGEN, INC.
    Inventors: Congxin Liang, Li Sun, Chung Chen Wei, Peng Cho Tang, Gerald McMahon, Klaus Peter Hirth, Jingrong Cui
  • Indolinone derivatives as protein kinase/phosphatase inhibitors
    Patent number: 6706709
    Abstract: The present invention relates to certain 2-indolinone compounds which modulate the activity of protein kinases (“PKs”) and phosphatases. The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Grant
    Filed: June 4, 2001
    Date of Patent: March 16, 2004
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, G. Davis Harris, Xiaoyuan Li
  • Human orthologues of Wart
    Publication number: 20040048349
    Abstract: The present invention relates in part to hWART nucleic acid molecules. The invention also relates in part to nucleic acid molecules encoding portions of hWART full-length proteins, nucleic acid vectors containing hWART nucleic acid molecules, recombinant cells containing such nucleic acid vectors, polypeptides purified from such recombinant cells, antibodies to such polypeptides, and methods of identifying compounds that modulate the function of an hWART polypeptide. Also disclosed are methods for diagnosing abnormal cell proliferative conditions in an organism using hWART-related molecules or compounds.
    Type: Application
    Filed: October 31, 2002
    Publication date: March 11, 2004
    Applicant: SUGEN, INC.
    Inventors: Gregory Plowman, Peter Flanagan
  • (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors
    Publication number: 20040039196
    Abstract: The present invention relates to (2-oxindol-3-ylidenyl)acetic acid derivatives which modulate the activity of protein kinases and are therefore useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Application
    Filed: June 13, 2003
    Publication date: February 26, 2004
    Applicant: SUGEN, INC.
    Inventors: Chung Chen Wei, Peng Cho Tang
  • 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
    Patent number: 6696448
    Abstract: The present invention relates to novel 3-(piperazinyl-benylidenyl)-2-indolinone compounds and derivatives and physiologically acceptable salts thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: February 24, 2004
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Laura Kay Shawver, Klaus Peter Hirth
  • Formulations for hydrophobic pharmaceutical agents
    Patent number: 6696482
    Abstract: The present invention features formulations, including liquid, semi-solid or solid pharmaceutical formulations, that improve the oral bioavailability of hydrophobic pharmaceutical agents, such as quinazoline-, nitrothiazole-, and indolinone-based compounds. Also featured are formulations for parenteral delivery of such hydrophobic pharmaceutical agents, as well as methods of making and using both types of formulations.
    Type: Grant
    Filed: March 5, 2001
    Date of Patent: February 24, 2004
    Assignee: Sugen, Inc.
    Inventors: Narmada Shenoy, Gregory S. Wagner
  • 3-heteroarylidenyl-2-azaindolinones active as protein tyrosine kinase inhibitors
    Patent number: 6696463
    Abstract: The invention relates to 3-heteroarylidenyl-2-azaindolinone compounds of the formula: wherein, A is selected from the group consisting of nitrogen, oxygen and sulfur; only one of B, D, E, F or G is nitrogen; Z is selected from the group consisting of oxygen, sulfur and NR11; or physiologically acceptable salts thereof; and wherein the groups R1-R7 are defined herein. The 3-heteroarylidenyl-2-azaindolinone compounds of the preferred embodiments of the present invention have improved hydrosolubility and are expected to modulate the activity of protein tyrosine kinases. The 3-heteroarylidenyl-2-azaindolinone compounds of the preferred embodiments of the present invention should be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: February 24, 2004
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Indolinone compounds as kinase inhibitors
    Patent number: 6689806
    Abstract: The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds of the invention. The invention also relates to methods of modulating the function of protein kinases using indolinone compounds of the invention and methods of treating diseases by modulating the function of protein kinases and related signal transduction pathways.
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: February 10, 2004
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Todd Anthony Miller, Shahrzad Shirazian, Chung Chen Wei, G. Davis Harris, Jr., Xiaoyuan Li, Congxin Liang
  • 3-methylidenyl-2-indolinone modulators of protein kinase
    Publication number: 20040024010
    Abstract: The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Application
    Filed: March 10, 2003
    Publication date: February 5, 2004
    Applicant: Sugen, Inc.
    Inventors: Pen Cho Tang, Li Sun, Todd Anthony Miller, Congxin Liang, Ngoc My Tran, Anh Thi Nguyen, Asaad Nematalla
  • Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
    Publication number: 20040018528
    Abstract: The present invention describes novel methods that measure in a mammal the level of at least one biomarker, such as a protein and/or mRNA transcript. Based on the level of at least one biomarker in a mammal exposed to a test compound, compared to the level of the biomarker(s) in a mammal that has not been exposed to a test compound, the ability of the test compound to inhibit tyrosine kinase activity can be determined. The invention also relates to novel methods, wherein a change in the level of at least one biomarker in a mammal exposed to a compound, compared to the level of the biomarker(s) in a mammal that has not been exposed to the compound, indicates whether the mammal is being exposed to, or is experiencing or will experience a therapeutic or toxic effect in response to, a compound that inhibit tyrosine kinase activity.
    Type: Application
    Filed: May 19, 2003
    Publication date: January 29, 2004
    Applicant: Sugen, Inc.
    Inventors: Alyssa Morimoto, Samuel DePrimo, Anne-Marie O'Farrell, Beverly D. Smolich, William C. Manning, Sarah A. Walter, James W. Schilling, Julie Cherrington
  • Bicyclic protein kinase inhibitors
    Patent number: 6683082
    Abstract: The present invention relates to novel 3-hetero-arylidene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: January 27, 2004
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
    Patent number: 6680335
    Abstract: The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds. The invention also relates to methods of modulating the function of protein kinases using indolinone compounds and methods of treating diseases by modulating the function of protein kinases and related signal transduction pathways.
    Type: Grant
    Filed: December 13, 2001
    Date of Patent: January 20, 2004
    Assignee: Sugen, Inc.
    Inventor: Peng Cho Tang
  • Polynucleotides encoding STE20-related protein kinases and methods of use
    Patent number: 6680170
    Abstract: The present invention relates to the nucleic acid molecules encoding an STE20-related family of novel protein kinases, ZC1, ZC2, ZC3, ZC4, STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, KHS2, SULU1, SULU3, GEK2, PAK4 and PAK5, segments and domains thereof, as well as various methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Mammalian nucleic acid molecules encoding these kinases are particularly disclosed, and more specifically human sources of these nucleic acids are disclosed.
    Type: Grant
    Filed: April 13, 1999
    Date of Patent: January 20, 2004
    Assignee: Sugen, Inc.
    Inventors: Gregory Plowman, Ricardo Martinez, David Whyte
  • Method for detecting remote homologues and novel kinases identified with the method
    Publication number: 20040009549
    Abstract: The present invention relates to novel methods for detecting remote polypeptide homologues. The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian kinases have been identified and their protein structure predicted.
    Type: Application
    Filed: December 31, 2002
    Publication date: January 15, 2004
    Applicant: Sugen, Inc.
    Inventors: Igor Vyacheslavovich Grigoriev, Sucha Sudarsanam
  • 4-aryl substituted indolinones
    Patent number: 6677368
    Abstract: The present invention relates to 4-arylindolinones, as well as pharmaceutical compositions thereof, capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. The present invention also relates to methods for treating protein kinase related disorders.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: January 13, 2004
    Assignee: Sugen, Inc.
    Inventors: Jingrong Cui, Ruofei Zhang, Hong Shen, Ji Yu Chu, Fang-Jie Zhang, Marcel Koenig, Steven Huy Do, Xiaoyuan Li, Chung Chen Wei, Peng Cho Tang
  • PYK2 related products and methods
    Publication number: 20040005648
    Abstract: The present invention features a method for treatment of an organism having a disease or condition characterized by an abnormality in a signal transduction pathway, wherein the signal transduction pathway includes a PYK2 protein. The invention also features methods for diagnosing such diseases and for screening for agents that will be useful in treating such diseases. The invention also features purified and/or isolated nucleic acid encoding a PYK2 protein.
    Type: Application
    Filed: June 19, 2003
    Publication date: January 8, 2004
    Applicants: Sugen, Inc., New York University
    Inventors: Sima Lev, Joseph Schlessinger
  • Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
    Publication number: 20040002534
    Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.
    Type: Application
    Filed: June 23, 2003
    Publication date: January 1, 2004
    Applicant: Sugen, Inc.
    Inventors: Ken Lipson, Gerald McMahon